Cargando…
Regulatory considerations for paediatric drug evaluation in China
The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in l...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163445/ https://www.ncbi.nlm.nih.gov/pubmed/37130653 http://dx.doi.org/10.1136/bmjpo-2022-001666 |
_version_ | 1785037882668351488 |
---|---|
author | Geng, Ying Li, Qiang Sun, Yan-Zhe Zhang, Hao Jiang, Yong-Lin Wang, Li-Qing Wu, Yue-E Zhao, Wei Yang, Zhi-Min |
author_facet | Geng, Ying Li, Qiang Sun, Yan-Zhe Zhang, Hao Jiang, Yong-Lin Wang, Li-Qing Wu, Yue-E Zhao, Wei Yang, Zhi-Min |
author_sort | Geng, Ying |
collection | PubMed |
description | The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in line with international standards but also had breakthroughs, innovations and Chinese characteristics. In this paper, the current setting of paediatric drug research and development in China and corresponding technical guidelines have been introduced from regulatory perspectives, and the accessibility of further improvement in regulatory strategies has also been discussed. |
format | Online Article Text |
id | pubmed-10163445 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-101634452023-05-07 Regulatory considerations for paediatric drug evaluation in China Geng, Ying Li, Qiang Sun, Yan-Zhe Zhang, Hao Jiang, Yong-Lin Wang, Li-Qing Wu, Yue-E Zhao, Wei Yang, Zhi-Min BMJ Paediatr Open Review The regulatory guidelines for the research and development of paediatric drugs are still evolving in China. The formulation of the guidelines started from learning and borrowing existing experience, and gradually changed to the exploration and improvement of local guidelines, which was not only in line with international standards but also had breakthroughs, innovations and Chinese characteristics. In this paper, the current setting of paediatric drug research and development in China and corresponding technical guidelines have been introduced from regulatory perspectives, and the accessibility of further improvement in regulatory strategies has also been discussed. BMJ Publishing Group 2023-05-02 /pmc/articles/PMC10163445/ /pubmed/37130653 http://dx.doi.org/10.1136/bmjpo-2022-001666 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Review Geng, Ying Li, Qiang Sun, Yan-Zhe Zhang, Hao Jiang, Yong-Lin Wang, Li-Qing Wu, Yue-E Zhao, Wei Yang, Zhi-Min Regulatory considerations for paediatric drug evaluation in China |
title | Regulatory considerations for paediatric drug evaluation in China |
title_full | Regulatory considerations for paediatric drug evaluation in China |
title_fullStr | Regulatory considerations for paediatric drug evaluation in China |
title_full_unstemmed | Regulatory considerations for paediatric drug evaluation in China |
title_short | Regulatory considerations for paediatric drug evaluation in China |
title_sort | regulatory considerations for paediatric drug evaluation in china |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163445/ https://www.ncbi.nlm.nih.gov/pubmed/37130653 http://dx.doi.org/10.1136/bmjpo-2022-001666 |
work_keys_str_mv | AT gengying regulatoryconsiderationsforpaediatricdrugevaluationinchina AT liqiang regulatoryconsiderationsforpaediatricdrugevaluationinchina AT sunyanzhe regulatoryconsiderationsforpaediatricdrugevaluationinchina AT zhanghao regulatoryconsiderationsforpaediatricdrugevaluationinchina AT jiangyonglin regulatoryconsiderationsforpaediatricdrugevaluationinchina AT wangliqing regulatoryconsiderationsforpaediatricdrugevaluationinchina AT wuyuee regulatoryconsiderationsforpaediatricdrugevaluationinchina AT zhaowei regulatoryconsiderationsforpaediatricdrugevaluationinchina AT yangzhimin regulatoryconsiderationsforpaediatricdrugevaluationinchina |